OBJECTIVES: The budget impact model (BIM) is recognized as a useful tool to help payers assess the economic value of new medicines approved for use.  Although they are not considered as robust as cost effectiveness models, they do allow for short-term estimates of pharmacy impact and potential costs/offsets with the inclusion of the new medicine on formulary.  Evolving IT platforms, such as the iPad, are offering new opportunities, but also changing end user expectations for these models.  Albiglutide is an investigational, once weekly, Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) for the treatment of Type 2 Diabetes (T2D).  We describe the development of an iPad application (app) derived from an excel-based BIM for use with US payer customers to inform access and reimbursement decisions for albiglutide. METHODS: An excel-based BIM estimating the 1-5 year impact of including albiglutide on formulary compared to other available GLP-1RA’s was developed as per guidance from AMCP and following ISPOR good research practices.  Given the increased use and demand for apps, we transformed the excel model into an app that would allow for modeling simulations to be run on an iPad adhering to these good practice guidelines.  RESULTS: The excel model was built according to the good practice guidelines and demonstrated the budget impact of introducing albiglutide for the treatment of T2D.  The BIM was designed in a way to allow for successful conversion into a standalone app that utilized an improved user interface for interactive discussions around the value of albiglutide with US payers.  CONCLUSIONS: The app version of the albiglutide BIM is a useful, complementary tool to the excel-based BIM.  The app maintains its functionality according to ISPOR and AMCP recommendations.